Suppr超能文献

一例长期使用抗凝剂后发生的抗凝相关肾病合并IgA肾病。

A case of anticoagulation-related nephropathy complicated by IgA nephropathy that developed following the long-term use of anticoagulants.

作者信息

Oyama Yuko, Iwafuchi Yoichi, Ito Yumi, Imai Naofumi, Narita Ichiei

机构信息

Department of Internal Medicine, Koseiren Sanjo General Hospital, 5-1-62 Tsukanome, Sanjo, Niigata, 955-0055, Japan.

Department of Nephrology, Saiseikai Niigata Kenoh Kikan Hospital, 5001-1 Kamisugoro Sanjo, Niigata, 955-0091, Japan.

出版信息

CEN Case Rep. 2025 Aug 8. doi: 10.1007/s13730-025-01020-2.

Abstract

Anticoagulant-related nephropathy (ARN) is a critical disease with clinical manifestations including acute kidney injury (AKI), which develops months after drug administration commences. The risk of ARN associated with direct oral anticoagulant agents (DOACs) is lower than that for warfarin, but there have been reports of ARN induced by DOACs other than dabigatran, such as edoxaban. We describe a patient with ARN caused by edoxaban, after the long-term use of warfarin and a switch from dabigatran, who had underlying IgA nephropathy with normal renal function. A 75-year-old man presented with AKI, with hematuria and proteinuria. He had never previously experienced urinary abnormalities or renal impairment. He was started on warfarin for atrial fibrillation 17 years previously, then switched to dabigatran for 11 years, and then edoxaban for 3 years. Three months before admission, he developed melena and hematuria. On the basis of his medical history and renal pathologic findings, he was diagnosed with ARN complicated by IgA nephropathy, with interstitial lesions and marked arteriosclerosis. After discontinuing edoxaban and methylprednisolone pulse therapy followed by oral prednisolone, his proteinuria diminished, and his renal dysfunction and hematuria were ameliorated. ARN can develop at any time in association with any DOAC, even in patients with normal renal function, and may be associated with anticoagulant overdose and subclinical IgA nephropathy. Therefore, careful monitoring of renal function and urinalysis is necessary for the prevention and early recognition of ARN, and dose reduction or a change in anticoagulant should occur when anticoagulant overdose or ARN is suspected.

摘要

抗凝相关肾病(ARN)是一种严重疾病,其临床表现包括急性肾损伤(AKI),在开始用药数月后出现。与直接口服抗凝剂(DOACs)相关的ARN风险低于华法林,但有报道称除达比加群外的其他DOACs(如依度沙班)也可诱发ARN。我们描述了一名长期使用华法林并从达比加群转换用药后,因依度沙班导致ARN的患者,该患者患有潜在的IgA肾病,肾功能正常。一名75岁男性出现急性肾损伤,伴有血尿和蛋白尿。他既往从未有过泌尿系统异常或肾功能损害。17年前他因房颤开始使用华法林,之后改用达比加群11年,然后使用依度沙班3年。入院前3个月,他出现黑便和血尿。根据其病史和肾脏病理检查结果,他被诊断为ARN合并IgA肾病,伴有间质病变和明显动脉硬化。停用依度沙班并进行甲泼尼龙冲击治疗后口服泼尼松龙,他的蛋白尿减少,肾功能障碍和血尿得到改善。ARN可在任何时间与任何DOAC相关联而发生,即使在肾功能正常的患者中也是如此,并且可能与抗凝药物过量和亚临床IgA肾病有关。因此,为预防和早期识别ARN,有必要仔细监测肾功能和进行尿液分析,当怀疑抗凝药物过量或ARN时,应减少剂量或更换抗凝剂。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验